Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Cassava Sciences Inc (FLNA) Price & Performance

ARK Genomic Revolution ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Cassava Sciences Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ARKGFLNA
Sector
Sector/ThematicHealth
52-Week High
$44.55$4.64
52-Week Low
$24.02$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.

Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA